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Engineered mosquitoes to fight mosquito borne diseases: not a merely
technical issue
Guido Favia*
Scuola di Bioscienze e Medicina Veterinaria; University of Camerino; Camerino (MC), Italy
Malaria, dengue and other mos-quito-borne diseases pose dramatic
problems of public health, particularly in
tropical and sub-tropical countries. His-
torically, vector control has been one of
the most successfully strategies to eradi-
cate some mosquito-borne diseases, as
witnessed by malaria eradication in Med-
iterranean regions such as Italy and
Greece. Vector control through insecti-
cides has been used worldwide; unfortu-
nately, it is losing effectiveness due to
spread of resistances. Control of mos-
quito-borne diseases through field-
releases of genetically engineered mosqui-
toes is an innovative and now feasible
approach. Genetically modified mosqui-
toes have already been released into the
wild in some regions, and protocols for
this release are on hand in others. Local
authorities are vigilant that transgenic
insects in the field are safe for human and
animal populations, and the public
engagement in every control program is
assuming a central role.
Introduction
Numerous species of mosquitoes are
vectors of human and animal pathogens
responsible for malaria, dengue, yellow
fever, chikungunya, filariasis and other
diseases. They are a major global concern
in public health, and integrated programs
centered on vector control provide an
effective barrier to their spreading.1-3
A paradigmatic example of a successful
vector control is malaria eradication in
Europe and North America. In the history
of the Italian Public Health, malaria eradi-
cation is unanimously regarded as one of
the major achievements. At the end of the
19th century, malaria was widespread in a
large part of Italy. Malaria deaths num-
bered 15,000–20,000 per year, and the
malaria cases amounted to 2 million, i.e.,
nearly 7% of the entire population.4 The
last outbreak occurred in Sicily in 1955,
and the last sporadic cases were reported
in 1962 in the same area.
A drastic reduction of malaria ende-
mism (anticipatory of a complete eradica-
tion) was mainly determined by the
approval of laws of strong social impact
approved by the Italian Parliament in the
first half of the 20th century. Two laws
were particularly effective. They regulated
the production and free distribution of
quinine, and promoted actions to reduce
the breeding sites of larvae of malaria
vectors.
Political decisions resulting in substan-
tial social and economic modifications
were of key importance for malaria eradi-
cation also in other European and North-
American countries.
An even more decisive factor for the
success of malaria eradication in Italy, was
the involvement of citizens and workers (a
matter that cannot be taken for granted
and needs ad hoc persuasive actions). In
Sardinia, for example, even though few
people had technical expertise, some peo-
ple was recruited and trained as disinfec-
tors, larva scouts, and sprayers while
others were enrolled to perform supply,
transport, and administrative services.5
This happened during the early stages
of the eradication campaign, when citizens
and workers got only general information
about the eradication program. This inad-
equate information resulted in a scarce
motivation among workers, and pushed
for a more exhaustive circulation of infor-
mation and a deeper consultation of
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municipal authorities and skilled
workers.5
In this regard it should be emphasized
that a fair and accurate information
regarding specific programs to fight vec-
tor-borne diseases is essential for their
implementation. On the contrary, lack or
incomplete information may strongly
affect program effectiveness. This is well
represented by example of New Delhi,
where a lack of proper communication on
a sterile male release program for the erad-
ication of Aedes aegypti turned out to be a
complete failure because of a climate of
suspicion based on false statements that
have gone accrediting over time.6
Transgenic Mosquitoes and
Malaria Control
To date, malaria control programs
based on the use of drugs and insecticides,
meet severe limitations due to resistance
developed by parasites and vectors. New
methodologies have been developed and
some of them are being evaluated for their
use in the field. In this context, particular
attention has been attracted by methodol-
ogies that are based on genetic modifica-
tions either of mosquitoes, and the
mosquito microbiota, and directed to
block transmission. Obviously, these
approaches raise several ethical implica-
tions that have to be properly addressed
prior to their structural integration in
malaria control programs.
People argue that much of the contro-
versy on biotechnological applications and
genetic engineering is a consequence of a
general inability to properly deal/cope
with ethical and social issues in a system-
atic way.
In 2005, Macer7 stated that: “The
approach to genetically modify insects raises
few intrinsic ethical issues; however, impor-
tant environmental and human health con-
cerns need to be assessed before release of any
GM insects. The policy that each community
adopts should be the product of open dia-
logue involving all sectors of society. It can be
expected that this process will take years and
not all communities will endorse genetic con-
trol approaches to insect vectors.”
Nevertheless, field release of Geneti-
cally Modified (GM) mosquitoes directed
to defeat dengue infection has already
been performed in the Cayman Islands,
Malaysia and, on a larger scale, Brazil.8
Ethical concerns about field release of
GM mosquitoes touch a variety of aspects,
some of which relate to technical prob-
lems. For example, “what about horizontal
and cross/inter-species gene transfer?”
Others problems reflect assessment of
unpredictable risks. Some people are wor-
ried that genetic modifications may alter
the mosquito blood feeding behavior.
Other concerns invest more the philo-
sophical and/or religious sphere. It is a dif-
fused opinion that humans should in no
way alter their ecosystem. Followers of
some religions are prevented from killing
insects. Other people consider any living
organisms (insects included) not a tool in
the hands of humans for “their own
purposes.”9
These doubts and concerns reflect dif-
ferent backgrounds relevant to experts in
the field, government officials, members
of institutions responsible for the control
of public health, ordinary citizens with
different degrees of education, and others.
Public engagement and consensus are
thus a strategic and pre-requisite to set-up
an effective campaign of field-release GM
mosquitoes. If a large public consensus
will run together with political decisions,
these interventions may become feasible
and will not give rise to disputes as
occurred in previous experiences.10
With more work preliminarily done to
define risk assessment, it will be easier to
properly inform public and representatives
of government and institutions.
In this frame, simulation modelling
appears to be particularly strategic. For
example, the use of semi-field studies per-
formed in large cages (also known as
MalariaSphere) may be of great efficacy in
evaluating dynamics of trans-gene spread-
ing and monitoring phenomena of hori-
zontal gene transfer (HGT). Some very
useful studies, while investigating the fea-
sibility of GM mosquitoes based
approaches do not propose field release.
One example refers to the study of Lavery
and colleagues aimed to i) establish a field
site for genetic control trials, among sev-
eral potential sites characterized by proper
dengue epidemiology and Ae. aegypti
ecology and ii) test the interaction of
genetically modified and local wild-type
mosquitoes, using both laboratory cages
and in large cage trials at the field site.11
This type of approach is very useful to
assess the relative fitness of GM mosqui-
toes and to monitor the spread of effector
genes intended to block pathogen trans-
mission and reduce/eliminate vector
populations.
We have recently carried out a survey
in Burkina Faso (West Africa) to assess the
receptiveness to the use of GMOs and
GM mosquitoes in particular.12 Burkina
Faso is one of the 48 African countries
that have signed the Cartagena Protocol
on Biosafety and adopted principles from
the African Union’s Model Law on Bio-
safety of 2001. Also in 2003 it introduced
transgenic cotton in relation to a project
that incorporated policies on public
engagement.
Our survey has clearly pinpointed that
the use of GM Mosquitoes would be wel-
come at the condition that the characteris-
tics of the GM mosquitoes are properly
specified and justified. On the other hand,
some people appeared to be not totally
aware of possible environmental negative
aspects consequent to the release of GM
Mosquitoes, as well as of how GM mos-
quitoes work once they are released in the
wild.
The data that we have collected in Bur-
kina Faso closely reflect those described by
Marshall and collaborators13 in relation to
a study performed in Mali. The majority
of the interviewed people were open to a
release of GM mosquitoes for malaria
control. However, they were eager to be
previously ensured about safety and effi-
cacy of the technology, and possibly
trough preliminary trials.
In terms of public consultation and
engagement, the Malaysian experience is a
good reference study. It shows that a cer-
tain degree of dissatisfaction is inherent in
this type of approaches, as pointed out
also by Subramaniam and collaborators14
in reporting that “Our [Their] experience
showed that despite executing a well-planned
transparent public engagement process that
was relevant for a release in an uninhabited
site, there was still some dissatisfaction from
some community groups.”
One more important aspect is related
on how researchers working with GM
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mosquitoes perceive the public involve-
ment on their research. This issue has
been properly addressed by Christophe
Boete through a questionnaire monitored
how scientists working on malaria and its
vector mosquitoes perceive public opinion
and how they evaluate public consulta-
tions on their research. Interestingly this
study pinpointed that even if malaria
researchers agree to interact with a non-
scientific audience, they are reluctant “to
have their research project submitted in a
jargon-free version to the evaluation and the
prior-agreement by a group of non-
specialists.”15
In conclusion, as underlined by Alphey
& Alphey 16 “It’ s not just the genetics,” and
the use of GM mosquitoes, as any new
technologies, should match public accep-
tance. Ethical, legal and social issues have
to be addressed upstream any field release,
so as it is mandatory to take in proper con-
sideration normative, cultural and epide-
miological characteristics of the region in
which the field trail is going to be per-
formed. In many cases, the commitment
of local people involves communities with
high levels of illiteracy and little knowl-
edge of the modes of transmission of
malaria and other mosquito-borne dis-
eases. Nevertheless, this commitment has
to be organized in such a way that these
communities are convinced to be the
major beneficiaries of the trial.
Given this context, the involvement of
governmental officers and local scientists
can be of enormous help to achieve a sus-
tainable and effective epidemiological
impact of the use of GM mosquitoes.
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